SCHEMBL167295

SCHEMBL167295

CN(C)C(=O)c1cc(OCc2ccccc2)c(C(=O)OCc2ccccc2)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TSHR P16473 2/20 0.45
CYP3A4 P08684 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
APP P05067 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168977 0.86 ALDH1A1 (0.57) KMT2AMEN1ALDH1A1TDP1L3MBTL1
SCHEMBL31363007 0.83 ALDH1A1 (0.53) RAB9AKMT2ASMN1; SMN2ALDH1A1TDP1
SCHEMBL382869 0.83 ALDH1A1 (0.53) RAB9AKMT2ASMN1; SMN2ALDH1A1TDP1
SCHEMBL23809724 0.83 ALDH1A1 (0.62) RAB9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL23796954 0.82 ALDH1A1 (0.66) KMT2ALMNAALDH1A1TDP1L3MBTL1
SCHEMBL24983866 0.80 ALDH1A1 (0.58) RAB9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL15984733 0.80 HTT (0.50) RAB9AKMT2ASMN1; SMN2ALDH1A1TDP1
SCHEMBL167521 0.78 ALDH1A1 (0.48) RAB9AKMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL17981664 0.78 ALDH1A1 (0.49) RAB9AKMT2ANPC1ALDH1A1TDP1
SCHEMBL12659544 0.78 ALDH1A1 (0.49) RAB9AKMT2ALMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 BRD4 122/4885RAB9A 700/4885KMT2A 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.